subject area of

• A multicentre, randomised phase III trial comparing protracted venous infusion (PVI) 5-fluorouracil (5-FU) with PVI 5-FU plus mitomycin C in patients with inoperable oesophago-gastric cancer  Academic Article
• A phase I trial of imatinib in combination with mFOLFOX6-bevacizumab in patients with advanced colorectal cancer  Academic Article
• A phase II open-label randomized study to assess the efficacy and safety of selumetinib (AZD6244 [ARRY-142886]) versus capecitabine in patients with advanced or metastatic pancreatic cancer who have failed first-line gemcitabine therapy  Academic Article
• A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma  Academic Article
• A randomized phase II study of FOLFOX with or without the MET inhibitor onartuzumab in advanced Adenocarcinoma of the stomach and Gastroesophageal junction  Academic Article
• Adjuvant therapy for cancer of the colon.  Academic Article
• An Australian translational Study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (AvastinTM) [ASCENT]  Academic Article
• Analysis of the time course and prognostic factors determining toxicity due to infused fluorouracil  Academic Article
• Antiemetic Effectiveness and Nausea and Vomiting Incidence During Capecitabine and Oxaliplatin Chemotherapy  Academic Article
• Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international randomised controlled trial of capecitabine, bevacizumab and mitomycin C  Academic Article
• Biomarkers of 5-fu response in colon cancer [Brief Commentary]  Comment
• Bleb vascularity following post-trabeculectomy subconjunctival bevacizumab: A pilot study  Academic Article
• Capecitabine and mitomycin C as third-line therapy for patients with metastatic colorectal cancer resistant to fluorouracil and irinotecan  Academic Article
• Capecitabine, Bevacizumab, and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study  Academic Article
• Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II)  Academic Article
• Changing management and survival in patients with stage IV colorectal cancer  Academic Article
• Correlation of extended RAS and PIK3CA gene mutation status with outcomes from the phase III AGITG MAX STUDY involving capecitabine alone or in combination with bevacizumab plus or minus mitomycin C in advanced colorectal cancer  Academic Article
• Customizing chemotherapy for colon cancer: the potential of gene expression profiling  Academic Article
• Does the chemotherapy backbone impact on the efficacy of targeted agents in metastatic colorectal cancer? A systematic review and meta-analysis of the literature  Academic Article
• Dose-intense weekly cyclophosphamide, methotrexate, 5-fluorouracil, vincristine and prednisolone (CMFP) in advanced breast cancer  Academic Article
• Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: The ESPAC-3 periampullary cancer randomized trial  Academic Article
• Effect of immunosuppressive agents on hepatocyte apoptosis post-liver transplantation  Academic Article
• Final results of Australasian Gastrointestinal Trials Group ARCTIC study: an audit of raltitrexed for patients with cardiac toxicity induced by fluoropyrimidines  Academic Article
• Gene Expression Profiling-Based Prediction of Response of Colon Carcinoma Cells to 5-Fluorouracil and Camptothecin  Academic Article
• Impact of KRAS and BRAF gene mutation status on outcomes from the phase III AGITG MAX trial of capecitabine alone or in combination with bevacizumab and mitomycin in advanced colorectal cancer  Conference Paper
• Management of Colorectal Cancer in Elderly Patients: Focus on the Cost of Chemotherapy  Academic Article
• Metabolic response to preoperative chemotherapy predicts prognosis for patients undergoing surgical resection of colorectal cancer metastatic to the liver  Academic Article
• Mitomycin C, Carboplatin and Protracted Venous Infusion 5-Fluorouracil in Advanced Oesophago–gastric and Pancreatic Cancer: Results of Two Phase II Studies  Academic Article
• Motesanib with or without panitumumab plus FOLFIRI or FOLFOX for the treatment of metastatic colorectal cancer  Academic Article
• Multicenter Randomized Phase III Trial Comparing Protracted Venous Infusion (PVI) Fluorouracil (5-FU) With PVI 5-FU Plus Mitomycin in Inoperable Pancreatic Cancer  Academic Article
• Neoadjuvant Capecitabine and Oxaliplatin Followed by Synchronous Chemoradiation and Total Mesorectal Excision in Magnetic Resonance Imaging–Defined Poor-Risk Rectal Cancer  Academic Article
• Neoadjuvant capecitabine and oxaliplatin before chemoradiotherapy and total mesorectal excision in MRI-defined poor-risk rectal cancer: a phase 2 trial  Academic Article
• Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer  Academic Article
• Oral versus intravenous fluoropyrimidines for colorectal cancer  Academic Article
• Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial  Academic Article
• Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial  Academic Article
• Phase II randomized, double-blind, placebo-controlled study of AMG 386 (trebananib) in combination with cisplatin and capecitabine in patients with metastatic gastro-oesophageal cancer  Academic Article
• Phase II study of capecitabine and mitomycin C as first-line treatment in patients with advanced colorectal cancer  Academic Article
• Primary invasive cancer of the vagina: Outcome and complications of therapy  Academic Article
• Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial  Academic Article
• Randomized phase II trial of parsatuzumab (Anti‐EGFL7) or placebo in combination with FOLFOX and bevacizumab for first‐line metastatic colorectal cancer  Academic Article
• Rapid selection against truncation mutants in yeast reverse two-hybrid screens  Academic Article
• Report of two protocol planned interim analyses in a randomised multicentre phase III study comparing capecitabine with fluorouracil and oxaliplatin with cisplatin in patients with advanced oesophagogastric cancer receiving ECF  Academic Article
• Squamous cell carcinoma arising in an ovarian mature cystic teratoma: A case report  Academic Article
• Standard Chemotherapy for Gastric Carcinoma: Is It a Myth?  Academic Article
• Survival Associated with 5-Fluorouracil–Based Adjuvant Chemotherapy among Elderly Patients with Node-Positive Colon Cancer  Academic Article
• Targeted chemoradiation in metastatic colorectal cancer: A phase i trial of 131i-hua33 with concurrent capecitabine  Academic Article
• The Value of Routine Serum Carcino-Embryonic Antigen Measurement and Computed Tomography in the Surveillance of Patients After Adjuvant Chemotherapy for Colorectal Cancer  Academic Article
• The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study  Academic Article
• Treatment of 5-fluorouracil refractory metastatic colorectal cancer: an Australian population-based analysis  Academic Article
• Use of Adjuvant Chemotherapy and Radiation Therapy for Rectal Cancer Among the Elderly: A Population-Based Study  Academic Article
• Variations in the use of adjuvant chemotherapy for node-positive colon cancer in the elderly: A population-based study  Academic Article
• Vascular endothelial growth factor D expression is a potential biomarker of bevacizumab benefit in colorectal cancer  Academic Article